# Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

> **NCT01118689** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Relapsed Multiple Myeloma
- Refractory Multiple Myeloma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** MLN0128

## Key facts

- **NCT ID:** NCT01118689
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-05
- **Final completion:** 2013-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2013-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118689, "Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01118689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*